Investors
Breaking News:
On October 21, 2019, during UEG week held in Barcelona, ABIVAX has reported Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study.
Information is available at the following link: https://www.abivax.com/investors/ueg-week-2019/
Share Profile
Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.
- ISIN code: FR0012333284
- Symbol: ABVX
- ICB Classification: Healthcare 4000/ Biotechnology 4573
- Market: Euronext Paris-Compartment C
- Type of Listing: continuous
- Number of outstanding shares: 11 808 939 as of 30 September 2019
- Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
- Eligible to French PEA PME
Analysts
LifeSci Capital Alpha Series:
Adam Evertts & David ShermanContact Adam Evertts / Contact David Sherman
goetzpartners securities:
Chris RedheadKepler Cheuvreux:
Damien Choplain